House Subcommittee Considers Cannabis Banking Barriers

The large amounts of cash cannabis businesses accumulate creates a security risk with predictable consequences, including armed robbery. Rep. Denny Heck (WA-10) was among those who urged Congressional action.

"We have the power in this committee to prevent murders and armed robberies, and we must use it. We must use it now, because we are already too late," Rep. Heck said.

Allowing cannabis-related businesses access to traditional banking services would enable cashless and online sales, which would eliminate the need for patients to carry cash, facilitate patients’ use of delivery services, and increase delivery drivers’ safety.

FDA Seeks Input on Cannabis Rescheduling

The WHO's critical review determined cannabis and its extracts should be moved from the most restrictive category. A separate, earlier determination found that cannabidiol (CBD) does not warrant any controls, as it has no abuse potential and is safe to use.

The WHO’s Expert Committee was scheduled to release its report earlier, so the delay may put off the vote of the Commission on Narcotic Drugs, which meets March 14-22. The next meeting is in December 2019.

In anticipation of the earlier date, the FDA is cutting off public comments on March 14. If the vote is delayed, the FDA says the comment period will be reopened.

The Trump administration has asked for public comments on cannabis rescheduling twice before.

Administration Establishing New Rules for CBD

The Farm Bill’s changes to the legal status of hemp and hemp extracts, including CBD, has started a process of developing and implementing new federal regulations. The U.S. Department of Agriculture (USDA) is holding a public “listening session” March 13, and Agriculture Secretary Sonny Perdue told the House Agriculture Committee that they will have rules in place to get hemp growing in 2020.

Before state hemp cultivation programs can be developed and approved by federal regulators, the USDA must produce guidelines for defining and testing hemp, certifying crops and land use, and disposing of plants and byproducts. For 2019, limited hemp cultivation will be allowed under the research program provisions of the 2014 Farm Bill, which is far more restrictive.

The federal Food and Drug Administration (FDA) also has a developing role in regulating hemp extracts such as cannabidiol (CBD). The FDA last month announced plans to hold an April meeting with stakeholders to address CBD regulation. FDA Commissioner Scott Gottlieb told a House subcommittee that a working group of agency experts is being formed to develop options for CBD, including the possibility of parallel regulations, one for pure pharmaceutical CBD isolates and another for lower concentrations as a food product or dietary supplement.

FDA published the notice in the Federal Register, putting off the vote of the Commission on Narcotic Drugs, which meets March 14-22. The next meeting is in December 2019.

In anticipation of the earlier date, the FDA is cutting off public comments on March 14. If the vote is delayed, the FDA says the comment period will be reopened.

The Trump administration has asked for public comments on cannabis rescheduling twice before.

The WHO’s Expert Committee was scheduled to release its report earlier, so the delay may put off the vote of the Commission on Narcotic Drugs, which meets March 14-22. The next meeting is in December 2019.

In anticipation of the earlier date, the FDA is cutting off public comments on March 14. If the vote is delayed, the FDA says the comment period will be reopened.

FDA published the notice in the Federal Register, putting off the vote of the Commission on Narcotic Drugs, which meets March 14-22. The next meeting is in December 2019.

In anticipation of the earlier date, the FDA is cutting off public comments on March 14. If the vote is delayed, the FDA says the comment period will be reopened.

The WHO’s Expert Committee was scheduled to release its report earlier, so the delay may put off the vote of the Commission on Narcotic Drugs, which meets March 14-22. The next meeting is in December 2019.

In anticipation of the earlier date, the FDA is cutting off public comments on March 14. If the vote is delayed, the FDA says the comment period will be reopened.

The WHO’s Expert Committee was scheduled to release its report earlier, so the delay may put off the vote of the Commission on Narcotic Drugs, which meets March 14-22. The next meeting is in December 2019.

In anticipation of the earlier date, the FDA is cutting off public comments on March 14. If the vote is delayed, the FDA says the comment period will be reopened.

The WHO’s Expert Committee was scheduled to release its report earlier, so the delay may put off the vote of the Commission on Narcotic Drugs, which meets March 14-22. The next meeting is in December 2019.

In anticipation of the earlier date, the FDA is cutting off public comments on March 14. If the vote is delayed, the FDA says the comment period will be reopened.

The WHO’s Expert Committee was scheduled to release its report earlier, so the delay may put off the vote of the Commission on Narcotic Drugs, which meets March 14-22. The next meeting is in December 2019.

In anticipation of the earlier date, the FDA is cutting off public comments on March 14. If the vote is delayed, the FDA says the comment period will be reopened.

The WHO’s Expert Committee was scheduled to release its report earlier, so the delay may put off the vote of the Commission on Narcotic Drugs, which meets March 14-22. The next meeting is in December 2019.

In anticipation of the earlier date, the FDA is cutting off public comments on March 14. If the vote is delayed, the FDA says the comment period will be reopened.

The WHO’s Expert Committee was scheduled to release its report earlier, so the delay may put off the vote of the Commission on Narcotic Drugs, which meets March 14-22. The next meeting is in December 2019.

In anticipation of the earlier date, the FDA is cutting off public comments on March 14. If the vote is delayed, the FDA says the comment period will be reopened.

The WHO’s Expert Committee was scheduled to release its report earlier, so the delay may put off the vote of the Commission on Narcotic Drugs, which meets March 14-22. The next meeting is in December 2019.

In anticipation of the earlier date, the FDA is cutting off public comments on March 14. If the vote is delayed, the FDA says the comment period will be reopened.

The WHO’s Expert Committee was scheduled to release its report earlier, so the delay may put off the vote of the Commission on Narcotic Drugs, which meets March 14-22. The next meeting is in December 2019.

In anticipation of the earlier date, the FDA is cutting off public comments on March 14. If the vote is delayed, the FDA says the comment period will be reopened.

The WHO’s Expert Committee was scheduled to release its report earlier, so the delay may put off the vote of the Commission on Narcotic Drugs, which meets March 14-22. The next meeting is in December 2019.

In anticipation of the earlier date, the FDA is cutting off public comments on March 14. If the vote is delayed, the FDA says the comment period will be reopened.

The WHO’s Expert Committee was scheduled to release its report earlier, so the delay may put off the vote of the Commission on Narcotic Drugs, which meets March 14-22. The next meeting is in December 2019.

In anticipation of the earlier date, the FDA is cutting off public comments on March 14. If the vote is delayed, the FDA says the comment period will be reopened.

The WHO’s Expert Committee was scheduled to release its report earlier, so the delay may put off the vote of the Commission on Narcotic Drugs, which meets March 14-22. The next meeting is in December 2019.

In anticipation of the earlier date, the FDA is cutting off public comments on March 14. If the vote is delayed, the FDA says the comment period will be reopened.

The WHO’s Expert Committee was scheduled to release its report earlier, so the delay may put off the vote of the Commission on Narcotic Drugs, which meets March 14-22. The next meeting is in December 2019.

In anticipation of the earlier date, the FDA is cutting off public comments on March 14. If the vote is delayed, the FDA says the comment period will be reopened.

The WHO’s Expert Committee was scheduled to release its report earlier, so the delay may put off the vote of the Commission on Narcotic Drugs, which meets March 14-22. The next meeting is in December 2019.

In anticipation of the earlier date, the FDA is cutting off public comments on March 14. If the vote is delayed, the FDA says the comment period will be reopened.

The WHO’s Expert Committee was scheduled to release its report earlier, so the delay may put off the vote of the Commission on Narcotic Drugs, which meets March 14-22. The next meeting is in December 2019.

In anticipation of the earlier date, the FDA is cutting off public comments on March 14. If the vote is delayed, the FDA says the comment period will be reopened.
Activist Profile: Joshua Crossney, Baltimore, Maryland

Joshua Crossney first got interested in the medical cannabis industry in 2015 when he realized that, compared to other fields of medicine and science, the research and testing standards for cannabis were lacking. At the time, Josh was working for a company that provides staffing solutions for environmental laboratories, so he had the skills and connections to bring people from traditional science and medicine into the cannabis industry. And he saw a critical need.

“It was alarming to realize that some states do not require any quality control on cannabis medicine,” Josh says. “That means patients with compromised immune systems can be exposed to contaminants from environmental factors and human error.”

He also realized quickly that there were few platforms other than general cannabis trade shows, so there was a need for a venue for researchers to come together to share information about new developments.

The next year, Josh formed CSC Events and launched the Cannabis Science Conference in Portland, Oregon. That first conference in October 2016 had just under 800 attendees and 75 sponsors. The 2018 conference in Portland, the third annual, had 3,000 attendees and 150 vendors.

“I’m committed to bringing in people with great technical knowledge who can be educated on cannabis, says Josh.

For 2019, the conference is expanding to two locations, with an April east coast show in Baltimore added to the Portland event in September.

“We’ve had great growth over the past three years, and we have seen many states on the east coast develop medical cannabis programs since then, so we wanted to branch out and bring our educational platform to this new market,” Josh says, “It is full circle to bring it back to Baltimore, where we’re based. The East Coast is really hungry for this.”

Josh is not just connecting research professionals, he is working to bring therapeutic cannabis solutions to children as a board member of Cannakids, an organization based in California that is supporting pediatric patients with conditions such as cancer and epilepsy.

“People have reservations about cannabis and children, even with debilitating conditions,” Josh says. “It may be controversial, but it shouldn’t be when compared to chemotherapy and other treatments.”

His work for children is Josh’s big passion, and he hopes that combining industry and advocacy can help protect the medical aspects of cannabis as adult-use regulations expand.

“The ‘regulate it like alcohol’ approach really scares me,” Josh says. “Not as a medicine? How would the sick children have access, if it’s regulated like alcohol?”

The Obama Administration recognized the need to allow banking services for cannabis-related businesses and released guidance in 2014 for how financial institutions might do business with them without being prosecuted. The guidance is non-binding so relatively few financial institutions have taken the risk of servicing cannabis-related businesses. As of October 2018, only 486 U.S. financial institutions were providing such services.

On Wednesday, March 20, panels will explore the financial and social barriers that medical cannabis patients face and discuss strategies to overcome them. The topic for the first panel is “The Experience of Being a Medical Cannabis Patient in the U.S.,” which will explore the financial and social hurdles that medical cannabis patients face, from the high cost of medicine to impacts on individual rights. The second morning session is “What in the World Is Happening? Medical Cannabis, CBD, and Hemp Global Markets,” which will examine global legal barriers, how international regulations and laws impact patients, and how changes to them will affect patients in the U.S.

Following lunch, a panel will consider “CBD, Medical Cannabis, Hemp Foods, and Adult Use: What Does It All Mean for Patients and Medical Professionals?” Experts will discuss misinformation about the legality of these products as well as barriers to access in these markets. The last panel of the afternoon will be “Advocacy in the Courts: Protecting Patients’ Rights,” which will cover current legal and judicial issues that medical cannabis patients face. Following that, key stakeholder groups will convene to discuss strategies for advancing safe access in 2019 and beyond.